Background and Aims: Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease characterized by persistent synovial inflammation, cartilage degradation, and joint destruction.Several studies have reported mitochondrial dysfunction, dysregulated autophagy, and inflammation in RA, but few have tracked their dynamics following therapy.The aim of our study was to evaluate the direct effect of methotrexate (MTX) on metabolic parameters and markers of autophagy and inflammation in patients with RA. Materials and Methods: Ten newly diagnosed RA patients were enrolled in the study.They were treated with MTX in optimally approved daily doses for six months.Conventional biochemical and immunological indicators, metabolic parameters, and biomarkers for inflammation and autophagy were examined at the start of treatment and after the follow-up period.Results: All examined clinical and laboratory parameters were improved after treatment.We observed decreased basal respiration (p=0.018) and adenosine triphosphate (ATP) production (p=0.03),along with a significant reduction in plasma levels of chitinase-3-like protein 1 (YKL-40) (p=0.007) and lysosomal-associated membrane protein 1 (LAMP1) (p=0.03)following MTX therapy.Strong correlations were found between LAMP1 and basal respiration (p=0.022,r=0.928);LAMP2 and ATP production (p=0.033,r=-0.886); and Disease Activity Score in 28 joints (DAS28) and proton leak (p=0.017,r=0.941) before therapy.After therapy, associations were observed between LAMP1 and spare respiratory capacity (p=0.003,r=0.919), and between the 7-joint ultrasound score (GUS7) and LAMP2 (p=0.027,r=0.692).Conclusion: In conclusion, we present novel data on correlations between mitochondrial functional parameters and autophagy-and inflammation-related proteins in RA patients after treatment with MTX.These pilot findings may pave the way for future clinical applications related to monitoring disease severity and treatment response.